CA-19-9 as an Emerging Marker of Ovarian Tumour: A Rare Entity
Published: May 1, 2019 | DOI: https://doi.org/10.7860/JCDR/2019/39751.12843
Alpana Singh, Astha Srivastava, Divya Chauhan, Rajeshwari Gautam, Gita Radhakrishnan
1. Assistant Professor, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital, Delhi, India.
2. Assistant Professor, Department of Obstetrics and Gynaecology, LHMC and SSK Hospital, New Delhi, India.
3. Senior Resident, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital, Delhi, India.
4. Senior Resident, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital, Delhi, India.
5. Director Professor, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital, Delhi, India.
Correspondence
Dr. Astha Srivastava,
Assistant Professor, Department of Obstetrics and Gynaecology, LHMC and SSK Hospital, New Delhi-110001, India.
E-mail: astha1402@gmail.com
Tumour markers are widely used in clinical practice for diagnosis; follow-up, prognosis and to predict recurrence of certain malignancies. Markers for ovarian cancer include CA-125 antigen, CA-15-3 antigen, and Carcino-Embryonic Antigen (CEA). CA-19-9 antigen is usually elevated in malignancies including colorectal carcinoma, pancreatic adenocarcinoma but significantly raised levels of <10,000 U/mL were seen in advanced stage of gastrointestinal malignancy. A reported case of 60-year-old female who had abnormally high levels of CA19-9 in the blood associated with mucinous carcinoma right ovary invasive endocervical type. At one month post surgery CA 19-9 dropped significantly. There are few case reports which have shown an association of raised CA19-9 with benign pathology but the present case is first case showing such high levels of CA19-9 associated with mucinous carcinoma of ovary. This highlights the fact that although CA19-9 is a marker of gastrointestinal malignancy; thorough evaluation to rule out ovarian malignancy in suspected cases should be done.
[
FULL TEXT ] | [ PDF]